🟦 He is a Board-Certified Surgical Oncologist at the University of California, San Diego, with advanced degrees in Clinical Oncology and Immuno-Oncology. His research is in Cancer Immunotherapy, Nanomedicine, and Cancer Stem Cells.
🟦 His research contributions encompass the discovery of cancer stem cell markers in T-cell acute lymphoblastic leukemia, the patenting of Notch1 oncogene therapies (WO2013044164), the discovery of highly immunogenic HLA-A2 restricted CTL epitopes, advancements in nanotechnology-based peptide delivery (PMID: 33102521), and demonstrating Rebecsinib's effectiveness in targeting ADAR1 p150, marking a significant leap in leukemia therapy by inhibiting stem cell generation (PMID: 36803553).
🟦 In his leadership roles, he served as the Dean and Distinguished Professor at Huhzou University Medical School where he has led teams in greatly promoting the development of disciplines and completing the mission of moving Clinical Medicine major enrollment forward from the second-tier to the first-tier. He also serves as the Director of Drug Discovery at UC San Diego in pioneering drug discovery in vivo research.
🟦 As an Associate Editor for "Frontiers in Immunology" and "Frontiers in Oncology," a Guest Editor for "Cancers," and an Editorial Board Member for "Oncology Research" and "Oncology Advances," he has shaped scientific discourse while also reviewing grants for the European Science Foundation.
🟦 Clinically proficient, he performs complex surgical procedures and has contributed to advances in bio-printed liver tissue transplantation. With over two decades of lab management experience, he has complied with regulatory standards for diverse research projects, including those sponsored by CIRM, Pfizer, and Johnson & Johnson, and has developed various cancer research models.
🟦 Expert in preclinical imaging and histological techniques, his interests outside the lab include reading, writing, and gastronomy, where he enjoys being a chef-helper 👨🍳.